Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
IMC-002 by ImmuneOncia Therapeutics for Solid Tumor: Likelihood of Approval
IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Data Insights
IMC-002 by ImmuneOncia Therapeutics for Lymphoma: Likelihood of Approval
IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Lymphoma. According to GlobalData, Phase I...